Table 3.

Pathological conditions involving multiple organ systems which may be amenable to therapy with montelukast, pranlukast, or zafirlukast.

System	Leukotriene receptor antagonist
	Montelukast	Pranlukast	Zafirlukast
Respiratory	(i) Bronchiolitis obliterans [139] (ii) Acute lung injury (ARDS) [134, 140] (iii) Eosinophilic-mediated lung inflammation [141] (iv) Cystic fibrosis [142]	(i) Pulmonary fibrosis [143, 144] (ii) Lung remodeling [145] (iii) Diffuse panbronchiolitis [146]	(i) COPD [133, 147] (ii) Bronchiectasis [148]
Gastrointestinal	(i) Eosinophilic gastroenteritis [136] (ii) Eosinophilic esophagitis [149] (iii) Irritable bowel syndrome [137] (iv) Portal hypertension [150]	(i) Gastric mucosal protection [151] (ii) Primary biliary cirrhosis [152] (iii) NSAID-induced intestinal damage [153]	Hepatorenal syndrome [154]
Neurological		(i) Alzheimer's disease [155, 156] (ii) Epilepsy [157] (iii) Acute cerebral ischemia [158, 159] (iv) Hypothermia-induced brain injury [160]	Autoimmune encephalomyelitis [161]
Dermatological	(i) Atopic dermatitis [162] (ii) Idiopathic urticaria [163]		Psoriasis [164, 165]
Cardiovascular	(i) Hypoxic myocardium [166] (ii) Atherosclerosis [138]
Immunological	Systemic mastocytosis [167]	Endotoxin-induced shock [168]
Other	(i) Graves' orbitopathy [169] (ii) Obstructive sleep apnea [170] (iii) Allergic conjunctivitis [137] (iv) Interstitial cystitis [137]	(i) Metastatic disease [171] (ii) Otitis media [172]	(i) Capsular contracture [173] (ii) Prostatitis [174] (iii) Candidiasis [175]

The relevant references are cited in parentheses.